Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

OKUTURLAR, Yıldız; Gunaldi, Meral; Kocoglu, Hakan; Hursitoglu, Mehmet; GEDİKBAŞI, Asuman; Acarer, Didem; Harmankaya, Ozlem; Kumbasar, Abdulbaki

doi:10.4103/0973-1482.235355

Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

Atıf İçin Kopyala

OKUTURLAR Y., Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14
Basım Tarihi: 2018
Doi Numarası: 10.4103/0973-1482.235355
Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK
İstanbul Üniversitesi Adresli: Evet

Özet

Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.